Parkinson DiseaseNCT05065060
Parkinson Progression Marker Initiative Online (PPMI Online)
An observational study of Parkinson Disease, run by Michael J. Fox Foundation for Parkinson's Research at 1 site in United States.
Trial summary
Parkinson Progression Marker Initiative Online (PPMI Online) is an observational study collecting participant reported information from people with and without Parkinson's disease (PD), for the goal of better understanding risk and predictive factors for PD. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Parkinson Disease
- What is being tested?
- Observation
- How many people
- 500,000 participants
- Where
- 1 siteUnited States
- Study dates
- 28 Jul 2021to Dec 2041
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: In PPMI Online, up to 500,000 participants with and without PD will be enrolled and contribute data longitudinally and cross-sectionally using a web-based platform.
Who may be able to join
- Parkinson Disease (PD) Participants:
- Male or female age 18 years or older.
- Has received a diagnosis of Parkinson's disease
- Participants without PD:
- Male or female age 18 years or older.
- Has not received a diagnosis of Parkinson's disease
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
UCSF Movement Disorders and Neuromodulation Center (MDNC)
San Francisco, California, 94143
UCSF, 877-525-7764
About this study
Official title: Parkinson's Progression Markers Initiative Online Study (PPMI Online)
Parkinson Progression Marker Initiative Online (PPMI Online) is an observational study collecting participant reported information from people with and without Parkinson's disease (PD), for the goal of better understanding risk and predictive factors for PD.
PPMI Online is part of the broader Parkinson Progression Marker Initiative aimed at identifying markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Read the detailed description
PPMI is a broad program that is expanding the goals of the original PPMI study, and will include this PPMI Online protocol, as well the PPMI Clinical [NCT04477785], PPMI Remote, PPMI Digital protocols (with external regulatory oversight). All participants in PPMI may be asked to participate in one or all of these protocols and their enrollment in these studies may occur in varying order. PPMI participants may also be asked to participate in additional PPMI companion studies (as they are developed), which may only involve a subset of PPMI participants based on their cohort designation
- Conditions
- Parkinson Disease
- Being tested
- Observation
- Keywords
- Parkinson, Neurodegenerative Disorder, Prodromal, At Risk, Participant Reported Outcomes
- Medical subject headings
- Parkinson Disease, Neurodegenerative Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ObservationOther
Observation
What is being measured
The primary outcome is the main question the study is designed to answer.
Unified Parkinson's Disease Rating Scale Ib & II
Evaluates self-reported motor and nonmotor Parkinson's disease symptoms
Measured: Baseline to 240 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2021
- Study start28 Jul 2021
- Primary completionDec 2041 (estimated)
- Study completionDec 2041 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 500,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Michael J. Fox Foundation for Parkinson's Research
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Caroline M Tanner, University of California, San Francisco
- Investigators
- Caroline Tanner, MD, PhD, Principal investigator, University of California, San FranciscoKenneth L Marek, MD, Principal investigator, Institute for Neurodegenerative Disorders
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05065060
- Sponsor's protocol ID
- PPMI-007
- Status last verified
- Sep 2026
- First submitted
- 2 Sep 2021
- Last updated
- 8 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Pierz KA, Aamodt W, Gochanour C, Kurth R, Brumm MC, Coffey CS, Heathers LE, Totten M, Doty RL, Marek K, Siderowf A; Parkinson's Progression Markers Initiative. Percentile scores for the revised University of Pennsylvania Smell Identification Test for 16,972 individuals 60 years of age and older. NPJ Parkinsons Dis. 2025 Oct 1;11(1):280. doi: 10.1038/s41531-025-01095-9.
PubMed 41034300
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Parkinson's Progression Markers Initiative Online Study (PPMI Online)
- ClinicalTrials.gov ID
- NCT05065060
- Acronym / sponsor ID
- PPMI-007
- Conditions
- Parkinson Disease
- Keywords
- Parkinson, Neurodegenerative Disorder, Prodromal, At Risk, Participant Reported Outcomes
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 500,000 participants (estimated)
- Lead sponsor
- Michael J. Fox Foundation for Parkinson's ResearchUniversity, hospital or other
- Study start
- 28 Jul 2021 (actual)
- Primary completion
- Dec 2041 (estimated)
- Study completion
- Dec 2041 (estimated)
- First posted
- 1 Oct 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Parkinson Progression Marker Initiative Online (PPMI Online) is an observational study collecting participant reported information from people with and without Parkinson's disease (PD), for the goal of better understanding risk and predictive factors for PD.
PPMI Online is part of the broader Parkinson Progression Marker Initiative aimed at identifying markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Detailed description
PPMI is a broad program that is expanding the goals of the original PPMI study, and will include this PPMI Online protocol, as well the PPMI Clinical [NCT04477785], PPMI Remote, PPMI Digital protocols (with external regulatory oversight). All participants in PPMI may be asked to participate in one or all of these protocols and their enrollment in these studies may occur in varying order. PPMI participants may also be asked to participate in additional PPMI companion studies (as they are developed), which may only involve a subset of PPMI participants based on their cohort designation
Study design
- Observational model
- Cohort
- Time perspective
- Other
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- In PPMI Online, up to 500,000 participants with and without PD will be enrolled and contribute data longitudinally and cross-sectionally using a web-based platform.
Key inclusion criteria (6 listed)
- Parkinson Disease (PD) Participants:
- Male or female age 18 years or older.
- Has not received a diagnosis of Parkinson's disease
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ObservationObservation | Other | – |
Primary outcome
Unified Parkinson's Disease Rating Scale Ib & II
Time frame: Baseline to 240 months
Evaluates self-reported motor and nonmotor Parkinson's disease symptoms
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2026.
- Derived from this study: PubMed 41034300Pierz KA, Aamodt W, Gochanour C, Kurth R, Brumm MC, Coffey CS, Heathers LE, Totten M, Doty RL, Marek K, Siderowf A; Parkinson's Progression Markers Initiative. Percentile scores for the revised University of Pennsylvania Smell Identification Test for 16,972 individuals 60 years of age and older. NPJ Parkinsons Dis. 2025 Oct 1;11(1):280. doi: 10.1038/s41531-025-01095-9.
- Individual participant dataSharing planned: Undecided
Related trials for Parkinson Disease
Active, not recruitingPhase 2
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Thymoma, Thymic Carcinoma
RecruitingPhase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Recruiting
Decoding the Neural Mechanisms Underlying Postural Instability and Gait Dysfunction in Parkinson's Disease
Parkinson Disease, Freezing of Gait
Enrolling by invitationPhase 1/2
Lithium for Parkinson's: an Extension Trial
Parkinson Disease
Recruiting
Genetics and Aerobic Exercise to Slow Parkinson's Disease Trial
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Caroline Tanner, MD, PhD principal investigator
University of California, San Francisco
Kenneth L Marek, MD principal investigator
Institute for Neurodegenerative Disorders
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Parkinson Disease, run by Michael J. Fox Foundation for Parkinson's Research at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact University of California, San Francisco (877-525-7764, info@ppmionline.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Unified Parkinson's Disease Rating Scale Ib & II (time frame: Baseline to 240 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05065060, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2026.